Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New Bladder-Sparing cancer treatment trial seeks to spare patients from surgery

NCT ID NCT07201675

Summary

This study is testing whether a combination of two drugs, vedisertib and toripalimab, can effectively treat muscle-invasive bladder cancer while allowing patients to keep their bladder. The goal is to see if this approach can control the cancer and avoid the need for complete surgical removal of the bladder. The study will enroll 59 adults with newly diagnosed cancer to receive the drug combination and closely monitor their response.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MUSCLE INVASIVE BLADDER CANCER (MIBC) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.